ENTA News and Press, Enanta Pharmaceuticals Inc. From 06/23/21

Enanta Pharmaceuticals (ENTA) announces new preclinical data for EDP-721, an oral hepatitis B virus ((HBV)) RNA destabilizer being developed for use in an all-oral combination regimen for HBV.The data demonstrate potent, selective and pangenotypic inhibition of HBV surface antigen (HBsAg), wi...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported new preclinical data for EDP-721, a novel, oral hepatitis B virus (HBV) RNA destabilizer being developed...

Positive 28-Day Data from First Two EDP-514 Dose Cohorts: 200 mg and 400 mg EDP-514 was Safe and Well-Tolerated with Pharmacokinetics Supportive of Once-Daily, Oral Dosing Patients Dosed with 400 mg EDP-514 Showed a Mean Reduction of 3.3 Logs in HBV DNA Enant...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two virtual investor...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the company will have a poster presentation showcasing preclinical data for EDP-721, a novel, poten...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at ...

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Nathalie Adda - Chief Medical Officer Conference Call Pa...

The following slide deck was published by Enanta Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Enanta Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

Image source: The Motley Fool. Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Q2 2021 Earnings Call May 6, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Enanta Pharmaceuticals Inc (ENTA) Q2 2021 Earnings Call Transcrip...

Updating the results from the first two dose cohorts of Part 2 of its Phase 1b study, Enanta Pharmaceuticals ([[ENTA]] -2.1%) said that its experimental therapy, EDP-514 yielded positive data in a certain segment of chronic hepatitis B virus ((HBV)) patients.The pharmacokinetics obs...